News und Analysen

Shares of Mirati Therapeutics (NASDAQ: MRTX) are up more than 27% as of 10:25 a.m. ET. The company released earnings after the markets closed on Tuesday. The healthcare stock is down more than 21%

Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines

Image source: The Motley Fool.

Invitae (NYSE: NVTA)Q2 2023 Earnings CallAug 08, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in

Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out

Canadian cannabis company Tilray Brands (NASDAQ: TLRY) has been on the right track ever since it merged with rival Aphria in 2021. From an operational standpoint, it had been consistently

Shares of Blueprint Medicines (NASDAQ: BPMC) were down more than 12% as of 12:45 p.m. on Wednesday after the healthcare company announced second-quarter earnings. The stock is still up more than 27%

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q2 2023 Earnings CallAug 01, 2023, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Fool.com contributor Parkev Tatevosian compares Nano Dimension (NASDAQ: NNDM) and Invitae (NYSE: NVTA) across critical financial variables, including valuation, to determine the better stock to buy

Biotech stocks are famously volatile, and investors needed to look no further than the performance of Novocure's (NASDAQ: NVCR) shares on Thursday for proof. The company's share price cratered by